Alexandra Garancher
Overview
Explore the profile of Alexandra Garancher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
707
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Morabito M, Larcher M, Cavalli F, Foray C, Forget A, Mirabal-Ortega L, et al.
EMBO Mol Med
. 2019 Jul;
11(8):e9830.
PMID: 31328883
Medulloblastoma (MB) is a pediatric tumor of the cerebellum divided into four groups. Group 3 is of bad prognosis and remains poorly characterized. While the current treatment involving surgery, radiotherapy,...
12.
Lee C, Rudneva V, Erkek S, Zapatka M, Chau L, Tacheva-Grigorova S, et al.
Nat Commun
. 2019 Jan;
10(1):332.
PMID: 30659187
Drugs that modify the epigenome are powerful tools for treating cancer, but these drugs often have pleiotropic effects, and identifying patients who will benefit from them remains a major clinical...
13.
Garzia L, Kijima N, Morrissy A, De Antonellis P, Guerreiro-Stucklin A, Holgado B, et al.
Cell
. 2018 Jun;
173(6):1549.
PMID: 29856958
No abstract available.
14.
Wang J, Garancher A, Ramaswamy V, Wechsler-Reya R
Annu Rev Neurosci
. 2018 Apr;
41:207-232.
PMID: 29641939
Brain tumors are the leading cause of cancer-related death in children, and medulloblastoma (MB) is the most common malignant pediatric brain tumor. Advances in surgery, radiation, and chemotherapy have improved...
15.
Garancher A, Lin C, Morabito M, Richer W, Rocques N, Larcher M, et al.
Cancer Cell
. 2018 Mar;
33(3):435-449.e6.
PMID: 29533784
Cancer cells often express differentiation programs unrelated to their tissue of origin, although the contribution of these aberrant phenotypes to malignancy is poorly understood. An aggressive subgroup of medulloblastoma, a...
16.
Garzia L, Kijima N, Morrissy A, De Antonellis P, Guerreiro-Stucklin A, Holgado B, et al.
Cell
. 2018 Feb;
172(5):1050-1062.e14.
PMID: 29474906
While the preponderance of morbidity and mortality in medulloblastoma patients are due to metastatic disease, most research focuses on the primary tumor due to a dearth of metastatic tissue samples...
17.
Dorard C, Estrada C, Barbotin C, Larcher M, Garancher A, Leloup J, et al.
Nat Commun
. 2017 May;
8:15262.
PMID: 28497782
NRAS and its effector BRAF are frequently mutated in melanoma. Paradoxically, CRAF but not BRAF was shown to be critical for various RAS-driven cancers, raising the question of the role...
18.
Pei Y, Liu K, Wang J, Garancher A, Tao R, Esparza L, et al.
Cancer Cell
. 2016 Mar;
29(3):311-323.
PMID: 26977882
Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a...
19.
Dehainault C, Garancher A, Castera L, Cassoux N, Aerts I, Doz F, et al.
Hum Mol Genet
. 2014 May;
23(19):5243-50.
PMID: 24858910
Retinoblastoma is a non-hereditary as well as an inherited pediatric tumor of the developing retina resulting from the inactivation of both copies of the RB1 tumor suppressor gene. Familial retinoblastoma...